The money will equip Nightstar to complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage clinical studies.
Chinese vaccine and biologic products developer and manufacturer Shenzhen Kangtai Biological Products has announced the pricing for an initial public offering (IPO) of shares to raise ¥138.2m ($20.08m) in gross proceeds.